Ismail WA, et al. - In patients with psoriasis and chronic hepatitis C (CHC) infection, researchers assessed the outcome of treatment with direct-acting antiviral agents (DAAs). Participants in the study were 34 CHC-naive patients with plaque psoriasis. For CHC treatment, all patients were given sofosbuvir plus daclatasvir once a day for 12 weeks. According to this observational prospective cross-sectional study, sofosbuvir plus daclatasvir is efficacious in hepatitis C virus eradication and symptom improvement in patients with CHC infection and psoriasis. Fatigue and headache were the most common adverse events. To evaluate this promising effect of DAAs, future large series studies are required.